N/A
N=12
Endocannabinoid and Psychological Responses to Yoga in Healthy Adults
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT03710577 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcome: Primary: Change in Plasma Concentration of N-arachidonoylethanolamine — -.013; -.655 pmol/mL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Yoga (Behavioral); Quiet Rest (Behavioral)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of Wisconsin, Madison
- Primary completion
- May 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Plasma Concentration of N-arachidonoylethanolamine |
-.013; -.655 | — |
| PRIMARY Change in Plasma Concentration of 2-Arachidonoylglycerol (2-AG) |
.032; -.008 | — |
| SECONDARY Change in Total Mood Disturbance as Measured by the Profile of Mood States |
-9.41; -7.17 | — |
| SECONDARY Change in State Anxiety as Measured by the State-Trait Anxiety Inventory |
-1.58; -1.92 | — |
| SECONDARY Change in Total Pain as Measured by the Short-form McGill Pain Questionnaire |
-1.50; 0.00 | — |
Summary
This study evaluates the acute effect of yoga on plasma levels of endocannabinoids and mood (i.e., mood disturbance, anxiety, pain) compared to one session of quiet rest. Participants completed one session of yoga and one session of quiet rest on two separate days.
Eligibility Criteria
Inclusion Criteria
- greater than or equal to 18 years old and < 45 years old and
- report being healthy.
Exclusion Criteria
- Being pregnant or planning to become pregnant,
- currently smoking,
- having a history of light headedness or fainting during blood draws or physical activity,
- having a history of chest pain during physical activity,
- having a bone, joint, cardiac, or other medical condition that a doctor has said may be worsened by physical activity,
- taking medications for any chronic diseases such as high blood pressure or diabetes,
- responding 'Yes' to any of the seven questions on the Par-Q.
Data sourced from ClinicalTrials.gov (NCT03710577). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.